No services found
No Products found
Make the most of PEGS US 2024 – Book a meeting with our team and start your journey to innovation!
From 8900€ < 2 months
Facing challenges in monoclonal antibody development? Streamline your monoclonal antibody development with ProteoGenix’s phage display custom services and get your antibodies in less than 2 months. Our service tackles common challenges in antibody development, such as immunogenicity and the complex humanization process, by offering direct access to human monoclonal antibodies. Our offerings include the world’s first immune phage display library derived from human cancer patient donors, alongside our diverse naïve libraries featuring antibodies from various species in formats like Fab, scFv, or VHH. With ProteoGenix, you’re assured of strong guarantees, delivering at least three high-affinity binders, meticulously screened for your application of choice—be it ELISA, WB, or Flow Cytometry. Our expertise, highlighted by over 500 successful projects and highly diversified libraries, positions us as leaders in phage display technology for therapy, research, and diagnostics. Partner with us for innovative solutions that promise satisfaction and accelerate your project’s success.
Rapid Turnaround
Get your antibodies in <2 months.
Innovative Cancer Library
Utilize the world’s first immune library derived from cancer patients for targeted antibody discovery.
Binding Guaranteed
At least 3 high-affinity binders.
IP Freedom
Full intellectual property rights to the custom antibodies generated.
Proven Expertise
Benefit from our vast experience with over 500 successful phage display projects.
Accelerated Discovery
Pre-built libraries reduce time to discovery.
Library Diversity
Access to extensive Naïve libraries from various species and formats (Fab, scFv, VHH).
End-to-End Support
Comprehensive phage display screening services from initial screening through to antibody development and production.
Quality Assurance
Exceptional in-frame frequency (>93%) ensures reliable and effective antibody discovery.
PhD-Level Support
Expert guidance from PhD account managers, ensuring your project’s success with informed decision-making.
In the realm of therapeutics, our phage display antibody services are designed to efficiently block or activate clinical targets. With the option of using naive or immune libraries, we provide tailored solutions for therapeutic antibody development, ensuring high diversity and developability within optimal timelines. Learn more about our therapeutic applications services.
Our custom phage display services extend to diagnostic applications, where precision and specificity are paramount. Utilizing high-diversity camelid and rabbit libraries, we excel in minimizing off-target binding, enabling the development of reliable diagnostic tools with enhanced sensitivity and specificity. Explore our diagnostic applications services.
ProteoGenix harnesses the power of diverse high-quality naïve libraries for phage display custom services, enabling the discovery of antibodies across various formats (scFv, Fab, VHH) and species. Our ELISA-based screening ensures the identification of high-affinity binders, with 4 to 6 rounds of panning to secure the best candidates for your research needs. Explore our Naïve Library Screening Service.
Our immune library service offers tailored construction and screening for unparalleled specificity and stability in antibody discovery. With library capacities reaching up to 10^16 different binders and the flexibility of scFv, Fab, and VHH formats, we ensure the identification of binders with optimal affinity through a meticulous biopanning process. After 3 to 5 rounds, we provide several high-affinity binders, with the option to expand the search if necessary. Discover our Immune Library Service.
Leveraging ProteoGenix’s phage display antibody development services ensure access to our proprietary libraries, which confer a unique competitive advantage since no other company has access to our banks, driving forward the discovery and development of groundbreaking antibodies for research, diagnostic, and therapeutic applications.
Since Omicron became widespread, more and more treatments have been rendered ineffective against SARS-CoV-2. To provide timely solutions to this crisis, we partnered with Aseem Healthcare and Trident Biopharm Solutions to develop a new broadly neutralizing antibody cocktail.
After extensive testing, the cocktail proved not only to be active against major variants but also to outperform currently FDA and EMA approved and authorized treatments.
EC50 values for each antibody tested at the concentration (μg/ml) at which 50% of the infection is neutralised. > 0.08*: The EC50 value could not be determined or extrapolated, due to maximal inhibition (close to 100%) maintained at the lowest tested concentration (0.08μg/ml). Shaded cells: More than 50% inhibition was observed even at the highest dilution.
GET A PDF REPORT
“I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage Display. They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns.
During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemic evolved.
Their proactivity was key to obtaining promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.”
Senior scientist at aTyr Pharma, USA
“All three of the antibodies you delivered were reformatted into IgGs and worked well. Interestingly two were d1 binders, and one was a d1/d2 binder when we domain mapped them here. They were good “protein X” blocking antibodies. But none were “protein Y” blockers. They express reasonably well. Overall we are quite happy with them.”
Alvin Chew, Research Fellow, Nanyang Technological University, Singapore
“We are developing a novel immunotherapy and needed a highly potent monoclonal antibody. Currently the development of a novel antibody requires lengthy and expensive humanization process. We thus decided to screen for binders a human antibody library via phage display screening instead of humanizing a murine antibody. Proteogenix proposed just that. We provided our purified target antigen and in only one month several high affinity binders were obtained. We were able to quickly clone and produce a monoclonal antibody from the sequences provided. What should have taken 6 to 8 months was done in 2 for a fraction of the cost and for an equivalent quality.”
Prof Jonathan Kurtis, MD, PhD, Chair, Department of Pathology and Laboratory Medicine, Brown University, USA
“I requested ProteoGenix’s services for the generation of antibodies against a malarial protein by phage display. Their naive human library, which is comprised of 368 donors, is a unique resource which was one of the criteria I used to select their company. They optimized their standard screening strategy to be able to identify two specific clones, that they then expressed with very high yields in their proprietary XtenCHOTM cell line. I highly appreciated their level of expertise and their commitment to go beyond expectations, and I would recommend them for their reactivity and the high quality of their services.”
Dr Lorena Arranz, Group Leader, UiT the Arctic University of Norway, Tromsø – NCMM Associate Investigator – SFF Center Director
“We requested ProteoGenix’s services for the development of antibodies against a specific surface protein by phage display. Their naive human library was built from 368 donors for maximized diversity. This unique quality and their reactivity convinced us to work with them. They successfully identified various candidates that all bound well and specifically to our antigen. I appreciated their expertise for the high quality of their services as well as their good responses to my questions for this project.”
Prof Johnny Ong Chin-Ann, MD, PhD, Group leader, National Cancer Centre, Singapore
“We have been working together with ProteoGenix since 2020. Using phage display, they helped our team to develop several antibodies with effective blocking effects. We are pleased with their services and look forward to continue working together with them as we advance our research and bring the biologics to clinical stage.”
Elevate your therapeutic antibody development with ProteoGenix’s human naïve antibody libraries: LiAb-SFMAX™, LiAb-SFa™, and LiAb-Fab™. These libraries are at the heart of our phage display custom services, offering an unparalleled resource for discovering human antibodies with exceptional specificity and affinity. Designed to streamline the path to innovative therapeutics, our libraries empower researchers to uncover antibodies that can be seamlessly integrated into therapeutic applications without the need for humanization. With ProteoGenix’s expertise in phage display antibody engineering services, you gain access to a treasure trove of antibody candidates ideal for addressing a wide range of human diseases. Explore the potential of our Human Naïve Antibody Libraries and harness the power of precision-engineered antibodies to advance your therapeutic projects.
Discover ProteoGenix’s LiAb-SFCANCERTM, the first-of-its-kind Cancer Immune Library, revolutionizing the fight against cancer. Sourced from 48 patients across 7 cancer types, including Prostate, Colorectal, Renal, Lung, Skin Cancer, Melanoma, and Acute Myeloid Leukemia, our library offers unparalleled access to over 3.81×10¹⁰ scFv and 3.72×10¹⁰ Fab clones. Tailored for researchers and innovators, our phage display custom services are designed to fast-track the development of innovative cancer diagnostics and therapeutics. By providing a unique glimpse into the human immune response to cancer, our library not only accelerates your research but also paves the way for next-generation cancer treatments. Explore the vast possibilities with the LiAb-SFCANCERTM Library and make a significant impact in oncology.
Discover ProteoGenix’s LiAb-SFAUTOIMMTM, the pioneering Autoimmune Antibody Phage Display Library, setting new standards in autoimmune disease research. Sourced from 42 patients across 7 autoimmune diseases, including Sjogren’s Syndrome, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Crohn’s Disease, and Ulcerative Colitis, our library grants exclusive access to over 1.08×10¹¹ scFv and 1.06×10¹¹ Fab clones. Designed for researchers and innovators, our phage display custom services are engineered to expedite the discovery and development of novel diagnostics and therapeutics for autoimmune diseases. Offering a deep dive into the human immune response to autoimmunity, the LiAb-SFAUTOIMMTM Library not only accelerates your research endeavors but also charts the course for the next generation of autoimmune treatments. Embrace the extensive possibilities with the LiAb-SFAUTOIMMTM Library and contribute to transformative advances in autoimmune disease management.
Amidst the ongoing fight against COVID-19, ProteoGenix stands at the forefront with our specialized COVID-19 Antibody Library. Designed to meet the urgent needs of researchers worldwide, our library streamlines the discovery of precise, high-affinity antibodies against SARS-CoV-2. Whether you’re developing rapid diagnostics, exploring therapeutic options, or crafting effective vaccines, our custom phage display services are your ally. Harness the power of our COVID-19 Antibody Library to fast-track your projects and contribute to global health solutions with confidence and clarity. Join us in this critical mission and leverage our expertise for your COVID-19 research endeavors.
ProteoGenix excels in mouse monoclonal antibody development through our sophisticated phage display services, leveraging the mouse’s immune system for comprehensive antibody discovery. Our mouse phage display screening services are engineered to rapidly identify and produce high-affinity, highly specific antibodies, crucial for advancing research, diagnostic, and therapeutic projects. By combining state-of-the-art technology with deep expertise, we offer a seamless pathway from antigen selection to the delivery of functional mouse antibodies, ensuring each project benefits from antibodies with optimal specificity and efficacy. This service is ideal for researchers looking to harness the well-characterized mouse immune system for the generation of monoclonal antibodies that can be further humanized for therapeutic applications. Explore the possibilities with our Mouse Monoclonal Antibody Development services and accelerate your path to discovery.
Rabbit monoclonal antibodies are known for their high affinity and specificity, making them a powerful tool in diagnostic applications. ProteoGenix leverages phage display screening services to develop rabbit monoclonal antibodies tailored to your research needs. Explore Rabbit Monoclonal Antibody Production.
ProteoGenix offers specialized phage display services for dog monoclonal antibody development, tapping into the unique canine immune system for precise antibody discovery. Our dog library phage display service efficiently identifies antibodies with high specificity and affinity, tailored for veterinary research and potential diagnostics uses. Embrace the advantages of our Dog Library for Phage Display to enhance your canine-focused projects.
ProteoGenix leads in custom cat monoclonal antibody development with our phage display services, specifically designed for feline research needs. Our cat antibody phage display service promises the delivery of three novel antibodies, verified to bind your target in under 7 weeks. We ensure the highest diversity and affinity for pinpointing the ideal antibody for research, diagnostic, or therapeutic applications in cats. This species-specific strategy is essential for precision in feline disease research and treatment, providing unmatched accuracy and reduced immunogenicity for therapeutic use in cats. Explore our Cat Monoclonal Antibody Services.
ProteoGenix offers advanced nanobody production services using camelids, exploiting their unique immune system to produce nanobodies with high specificity and stability. Camelid antibodies, due to their small size and unique structure, are ideal for targeting difficult-to-reach antigens, offering promising avenues for both anti-cancer therapies and anti-infectious treatments. Learn more about our Camelid Nanobody Production.
ProteoGenix expands its phage display capabilities to pig monoclonal antibody development, capitalizing on the unique immune response of pigs. This approach is not arbitrary; pigs are genetically similar to humans, sharing a comparable immune system and organ sizes, making them ideal models for biomedical research. This similarity allows for the discovery of antibodies with exceptional specificity and affinity, crucial for advancing research, diagnostics, and therapeutics across both veterinary and human medicine. Our pig phage display service is specifically designed to rapidly generate high-quality antibodies, suitable for a wide array of applications. By exploring our Pig Phage Display Services, researchers unlock new avenues in swine health and contribute valuable insights into human biomedical research, bridging gaps in understanding and treatment of complex diseases.
Unlock the potential of camelid antibodies with ProteoGenix’s VHH screening service. VHH, or nanobodies, are distinguished by their small size, high stability, and exceptional tissue penetration capabilities, making them ideal for therapeutic, diagnostic, and research applications. A significant advantage of these single-domain antibodies is their unique ability to access and bind to cryptic epitopes that are typically inaccessible to conventional antibodies. This characteristic is particularly valuable in developing highly specific and effective treatments and diagnostics. Our VHH phage display custom services leverage these attributes for their exceptional specificity and affinity. Explore the transformative power of our VHH Screening Service and harness the versatility of nanobodies in your projects, taking advantage of their unparalleled precision in targeting hidden aspects of disease pathology.
ProteoGenix’s scFv phage display services provide a flexible and effective approach to antibody discovery. Single-chain variable fragments (scFv) combine the variable regions of heavy and light chains with a short peptide linker, offering a compact format that retains the antigen-binding specificity of conventional antibodies. Our scFv phage display screening services are designed to rapidly identify high-affinity scFvs for a wide range of applications. Discover the potential of our scFv Phage Display Service to accelerate your antibody development process.
Experience the advantages of fragment antigen-binding (Fab) antibodies with ProteoGenix’s Fab phage display screening. Fabs, consisting of a light chain and part of a heavy chain, offer an ideal balance between size and functionality, providing excellent antigen specificity without the Fc region. This makes them suitable for diagnostic applications where avoiding Fc-mediated effects is crucial. Our Fab phage display custom services are tailored to identify Fabs with high specificity and affinity, streamlining the path to discovery. Explore our Fab Phage Display Screening Service for your next project.
Phage display is a biotechnological technique that uses bacteriophages to display proteins on their surface while linking them to their genetic information. By inserting a gene for a desired protein into a phage coat protein gene, the phage can present the protein externally and carry the gene internally. This method is crucial for studying interactions such as protein-protein, protein-peptide, and protein-DNA, using in vitro selection similar to natural selection. Crucially, phage display is widely used to select antibodies against specific antigens, a key process in protein-protein interaction studies. This is especially important for developing therapeutic antibodies, as it allows for the discovery of antibodies that are highly specific and have a strong affinity for their target antigens, streamlining the path to innovative treatments.
Phage display offers several key advantages:
Phage display is widely utilized in:
The benefits of using Phage Display for therapeutic antibody development are significant and multifaceted. Unlike traditional hybridoma techniques, phage display technology facilitates the creation of fully human antibodies directly. This direct approach eliminates the need for subsequent humanization processes, offering a streamlined path from discovery to development. Here are the key advantages:
A phage library is a comprehensive collection of the antibody repertoire from a specific host species, crucial for antibody discovery and research. These libraries are typically derived from B lymphocytes (B cells) or peripheral blood mononuclear cells (PBMCs), which are isolated using density gradient centrifugation. The extracted cells undergo mRNA isolation and cDNA synthesis, providing a high-quality DNA template for PCR amplification of antibody-encoding genes, including the variable light (VL) and variable heavy (VH) chains.
Antibody libraries can be formatted in various ways, such as VHH (from camelid species), Fab (antigen-binding fragment), and scFv (single-chain variable fragment). The Fab and scFv formats necessitate a random pairing of VH and VL chains, a step required due to the loss of this information during the library’s construction.
Antibody libraries are categorized into several types based on their source and method of generation:
Antibody libraries are exceptionally versatile tools that, through display techniques, enable the detailed study of antibody-ligand interactions. Consequently, these libraries are instrumental in discovering antibodies for therapeutic, diagnostic, and research purposes. Furthermore, when mutagenesis is employed, antibody libraries become a powerful method for engineering specific antibody characteristics, such as enhanced affinity and improved developability.
Naïve antibody libraries are a valuable resource for antibody discovery, offering a balance alongside immune or synthetic libraries. Their key advantage is the diversity they offer, derived from the antibody repertoires of multiple donors or animals, potentially including up to 10^11 different clones. This diversity facilitates the identification of antibodies with a wide range of functionalities, capable of recognizing a broad spectrum of antigens. However, it’s important to note that immune libraries also play a crucial role, especially when targeting specific antigens that require a more focused approach.
The preference for naïve libraries in generating antibodies with novel functions stems from their ability to be used across multiple projects and against various antigens, thanks to their comprehensive coverage of potential antibody sequences. While the construction of naïve libraries is a labor-intensive process, their one-time creation offers long-term utility, making them a cost-effective choice for diverse antibody discovery endeavors.
In contrast, immune libraries are tailored for specific projects where high antibody affinity is crucial. Although they provide antibodies with enhanced specificity and affinity due to the immunization process, their use is generally limited to the project they were created for, which can make them less cost-efficient compared to the reusable nature of naïve libraries.
Antibody libraries are cloned using a meticulous process that begins with the collection of genetic material from a source, such as B lymphocytes from immunized or non-immunized hosts for immune and naïve libraries, respectively. The process involves several key steps:
In the M13 phage, proteins or peptides are attached to one of its capsid proteins, either the minor coat protein pIII (gp3) or the major coat protein pVIII (gp8). With only 5 copies of pIII per phage but 2700 copies of pVIII, pIII-linked fusions are displayed at a lower density, making them ideal for isolating high-affinity binders. In contrast, pVIII-linked constructs, due to their higher display density, are more suitable for identifying binders of lower affinity. The pIII system, however, faces a challenge due to its crucial role in the phage’s infectivity. M13 binds to E. coli through interactions involving pIII and the F factor, necessitating the preservation of pIII’s function to ensure the replication of selected phages. This issue is addressed by employing phagemid systems in combination with helper phages. Phagemids are simplified vectors that carry:
Meanwhile, helper phages provide all necessary components for phage infectivity and assembly but exclude the fusion protein linked to pIII and have a modified, less efficient replication origin. This arrangement allows for the production of virions that display both native pIII and the pIII-linked fusion proteins, typically in 1 to 5 copies, offering a balanced approach to phage display.
Our antibody libraries, instrumental in identifying molecules with unique functionalities, are indeed available for acquisition. ProteoGenix offers Naïve and Immune Antibody Library Kits, which include:
Absolutely, we specialize in creating tailor-made libraries from biological samples such as PBMCs or RNA, which can either be procured by us or supplied by the client. Clients have the flexibility to select from an array of formats including scFv, Fab, or VHH, and from a diverse range of species like rabbit, mouse, camel, and alpaca.
Leveraging our comprehensive capabilities, we provide every client with the option to internally synthesize antigens. Our facility is equipped to produce a wide range of antigens including peptides, proteins, small molecules, and even cells, specifically for use in phage display endeavors. This approach significantly shortens the timeline for phage display projects.
The choice of antigen for phage display is crucial and varies based on the specific application and the antigen’s characteristics. For example, targets for clinical applications are frequently complex, membrane-bound proteins. Achieving success in phage display in these scenarios often hinges on the antibody’s capacity to recognize the antigen in its native conformation. Therefore, whole cells that overexpress the target antigen are typically more effective than recombinant proteins for these purposes. Conversely, for antibodies aimed at analytical, diagnostic, or research uses, where antigens might be denatured for analysis (such as in Western Blotting), employing peptides as targets in phage display might be the preferable strategy.
Upon request, we can provide additional services, including:
With our naïve libraries’ vast diversity and a refined protocol for effective antibody phage display, we assure the identification and delivery of a minimum of three distinct binders targeting your antigen in every phage display campaign. Should this not be achieved, clients are only responsible for a portion of the service fee.
Monoclonal Antibody Humanization services Antibody Affinity Maturation solutions ADC development services Bispecific Antibody services
Hybridoma development services – ProteoGenix B-CELL SORTING – ProteoGenix Recombinant Antibody Services – ProteoGenix
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.